Year-end Sale % OFF 
Abstract
Ganciclovir and valganciclovir are first-line treatments for cytomegalovirus in immunocompromised children; however, the optimal therapeutic target remains unclear. This review identified 6 studies that showed clearance of cytomegalovirus viremia occurs with a median area under the concentration-time curve (AUC24) between 23 and 70 μg·h/mL, with no clear correlation with efficacy or toxicity.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
